Eyenuk To Provide Artificial Intelligence (AI) Eye Screening to Thousands of Italians Through Collaboration With Ambrosian Ophthalmic Center in February
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it is providing EyeArt® AI Eye Screening as part of the Month of Prevention of Diabetic Retinopathy (DR) and Maculopathy taking place throughout Italy in February. The collaboration between the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk™ is sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society.
During February, 30 centers across Italy will offer screening for DR using the EyeArt AI Eye Screening System, the most-extensively validated AI technology for autonomous detection of DR, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
DR is a complication of diabetes and the main cause of vision impairment and blindness among working-age adults. It occurs when high blood sugar levels lead to damage in the blood vessels of the retina, the light-sensitive tissue at the back of the eye. Annual eye screening is recommended for people living with diabetes since DR can progress silently without any perceptible symptoms or vision deterioration.
“Early detection of DR is an important part of managing care for millions of people with diabetes, yet less than half of the people with diabetes see an eye doctor on an annual basis. AI Eye Screening can make early detection of DR more accessible, allowing patients to seek treatment and likely save their vision,” explains Dr. Lucio Buratto, scientific director of CAMO.
The EyeArt AI Eye Screening System is designed to make it possible for any physician to quickly and accurately detect referable DR patients in less than one minute during a diabetic patient’s regular exam. This helps remove the biggest obstacle to annual DR screening and diagnosis: patient compliance. With the EyeArt System, physicians can identify patients with vision-threatening DR in-clinic, in real time, so they can be immediately referred to a vision specialist for treatment to save their sight. The EyeArt System uses AI algorithms to autonomously analyze images of the eye taken with a retinal camera. This advancement can enable timely detection of vision-threatening DR by a nurse or non-specialist and eliminate the need for an eye care expert to carefully grade patient’s retinal images.
“Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy,” says Kaushal Solanki, CEO of Eyenuk. “We are grateful for this opportunity to partner with these esteemed organizations in Italy to enable early detection of DR, thus advancing our mission with a critical step towards eliminating preventable blindness.”
For more information about the free AI Eye Screenings and the Month of Prevention of Diabetic Retinopathy and Maculopathy, please visit http://www.maculopatie.com/.
About Diabetic Retinopathy (DR)
DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease. At first, DR progresses without any symptoms at all, but eventually it can cause blindness. The condition can develop in anyone with type 1 or type 2 diabetes.i It is estimated that one-third of all patients living with diabetes will develop the blinding disease,ii making it the leading cause of vision loss in working-age adults.iii
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, validated in real world clinical studies with over 160,000 patient visits and over a million images. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
EyeArt has CE marking and has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada. In the U.S., the EyeArt® System is limited to investigational use only.
EyeArt® is a registered trademark of Eyenuk Inc.
ii Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909
iii Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47:171-188. doi: 10.1159/000329603
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gilead Announces Latest Data in Ongoing HIV Cure Research Program23.7.2019 20:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses
Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 15:30:00 CEST | Press release
Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu
Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 15:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These
Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 15:00:00 CEST | Press release
Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol
Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 14:12:00 CEST | Press release
US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing
Andersen Global Expands into Ghana23.7.2019 13:30:00 CEST | Press release
Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt